← Back to Search

PI3K Inhibitor

Duvelisib for COVID-19

Phase 2
Waitlist Available
Led By John DiPersio, M.D., Ph.D.
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
as a positive test for SARS-CoV-2 RNA detected by RT-PCR collected from the upper respiratory tract (e.g. nasopharyngeal, nasal, oropharyngeal swab, or saliva) and, if possible, the lower respiratory tract (sputum, tracheal aspirate, or bronchoalveolar lavage), analyzed by a CLIA certified lab with an FDA approved assay.
Chest imaging with ≥ 50% lung involvement
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through 29 days
Awards & highlights

Study Summary

This trial is testing if a new drug could help people with severe or critical COVID-19. The drug is designed to reduce inflammation and help the body fight the virus.

Eligible Conditions
  • COVID-19
  • Coronavirus

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through 29 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and through 29 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Survival as Measured by Number of Participants Alive Through 28 Days
Secondary outcome measures
Duration of Vasopressors Use
Duration of Ventilator Use
Duration on Renal Replacement Therapy
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: DuvelisibExperimental Treatment2 Interventions
-Duvelisib 25 mg twice daily for up to 10 days.
Group II: PlaceboPlacebo Group2 Interventions
-Placebo 25 mg twice daily for up to 10 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Duvelisib
2016
Completed Phase 3
~750
Peripheral blood draw
2017
Completed Phase 2
~60

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,928 Previous Clinical Trials
2,296,941 Total Patients Enrolled
26 Trials studying COVID-19
20,210 Patients Enrolled for COVID-19
Verastem, Inc.Industry Sponsor
38 Previous Clinical Trials
2,570 Total Patients Enrolled
1 Trials studying COVID-19
47 Patients Enrolled for COVID-19
John DiPersio, M.D., Ph.D.Principal InvestigatorWashington University School of Medicine
3 Previous Clinical Trials
97 Total Patients Enrolled
1 Trials studying COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby Mar 2025